Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: S6 kinase 1 inhibitors - Sentinel Oncology

Next Previous
Drug Profile

Research programme: S6 kinase 1 inhibitors - Sentinel Oncology

Alternative Names: FS 115; p70S6 inhibitors - Sentinel; p70S6K1 inhibitor - Sentinel; S6K1 inhibitors - Sentinel

Latest Information Update: 28 Sep 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sentinel Oncology
  • Class Small molecules
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Triple negative breast cancer

Most Recent Events

  • 28 Sep 2020 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in United Kingdom (PO)
  • 02 Dec 2016 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Breast cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 09 Aug 2016 Preclinical trials in Triple negative Breast cancer in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top